RIPK3 and colitis: Similarly, a RIPK3 inhibitor has been shown to mitigate the intensity of experimental colitis and decrease inflammation through the suppression of the inflammatory response and necroptosis [70], indicating that RIPK3 may be involved in the pathogenesis of necroptosis-induced UC.